Navigation Links
Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
Date:3/27/2008

h, cell differentiation and cell survival. KRX-0401, which is currently in Phase 2 clinical development for multiple tumor types, is expected to move into a Phase 3 clinical program in 2008. The Company also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

As the Company has indicated in its public filings, among other things, clinical trials have a high risk of failure. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in advanced clinical trials, even after achieving what appeared to be promising results in earlier trials.

Furthermore, as indicated in previous filings, interim results of preclinical or clinical studies do not necessarily predict their final results, and acceptable results in early studies might not be obtained in later studies. Drug candidates in the later stages of clinical development may fail to show the desired safety and efficacy traits despite positive results in initial clinical testing.

Additionally, as indicated in previous filings, there can be no assurance that the results from the Sulonex Phase 3 and/or Phase 4 study will track the data from the pilot Collaborative Study Group Phase 2 study or the DiNAS Phase 2 study. Results from these earlier Sulonex studies may not be indicative of results from future clinical trials.

Some of the statements included in this press release anticipating future clinical and business prospects may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully adjust our strategy
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
2. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
5. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
6. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
7. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
11. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the ... Estimates and Forecasts, 2012-2018"  report to their offering. ... by 2016. The North America ... while Europe claims approximately 25% ...
(Date:12/15/2014)... and HERZLIYA PITUACH, Israel , Dec. ... IMNP ) announced today that its Board of ... succeeding Dr. Daniel Teper who continues as Chief ... of Immune,s Board of Directors since 2013. Immune,s ... delighted to represent the interest of shareholders and to continue ...
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014   ... SAN and NYSE: SNY) are collaborating with nationally-recognized patient ... Counts , an awareness program that will gauge how ... risks associated with high LDL-C (bad cholesterol).  American adults ... to take a brief poll and answer a few ...
Breaking Medicine Technology:Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... moms who were exposed to high levels of air pollution ... autism, a U.S. study suggests. Researchers found that of ... 2002, those exposed to the most air pollution during pregnancy ... developed autism. And exposure during the third trimester, specifically, showed ...
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- Prostaglandin analogue eye drops ... reduce the risk of vision loss in patients with ... researchers led by David Garway-Heath, of the Moorfields Eye ... outcomes for more than 500 people newly diagnosed with ... disease and one of the leading causes of blindness. ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... 17, 2014 HeartMath® Inc., recognized ... stress, heart rate variability (HRV), heart coherence and ... extensive HRV databases and algorithms to chipset manufacturers ... enable HeartMath’s partners to offer its HRV solutions, ... as well as its normative HRV databases and ...
(Date:12/17/2014)... 2014 No matter how far modern ... eradicate the head louse parasite—a common childhood malady and ... year between six and twelve million individuals will suffer ... removal treatment company comes to the rescue, providing an ... With its track record of customer service, and effectiveness ...
Breaking Medicine News(10 mins):Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... Personal Protective Equipment Conference 2009 (PPE 2009), which ... in Fort Lauderdale, FL, November 17 - 19, 2009, ... networking resource for firefighters, law enforcement officers, military personnel, ... technicians, veterinary specialists, rescue team members, and other first ...
... , , ... supporting breast cancer research and awareness programs, Hard Rock International ... )winner, breast cancer survivor and multi-platinum recording artist, as its ... PINKTOBER program will also be ...
... , , Atlanta to Serve as ... NEW YORK , Sept. 14 ... the Center for AIDS Research at Emory University (CFAR) in Atlanta, Georgia will ... global scientific conference focused on AIDS vaccine research. AIDS 2010 is to ...
... for Down syndrome on the horizon promising to be safer, ... medical community must come together and engage in dialogue about ... leading article published Online First by Archives of Disease ... genetics fellow at Children,s Hospital Boston, the article shows a ...
... SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: ... has entered into a strategic relationship with Allscripts (NASDAQ: ... (e-prescribing) options available to SXC,s healthcare benefits management customers. ... plans, employers, government agencies, pharmacy benefit managers and pharmacies ...
... Sept. 14 A call for participants has been issued in ... upon the work the IMIA started in the 1980s with the ... final written exam pilot in support of national certification. , ... and rating of test items have been finalized, it is important ...
Cached Medicine News:Health News:Personal Protective Equipment Conference Set for November 17 - 19 in Fort Lauderdale 2Health News:Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER(TM) Campaign Featuring Melissa Etheridge, The Bangles, Melanie C, Joss Stone And More 2Health News:Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER(TM) Campaign Featuring Melissa Etheridge, The Bangles, Melanie C, Joss Stone And More 3Health News:Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER(TM) Campaign Featuring Melissa Etheridge, The Bangles, Melanie C, Joss Stone And More 4Health News:Center for AIDS Research at Emory University to Serve as Local Host of AIDS Vaccine 2010 2Health News:Center for AIDS Research at Emory University to Serve as Local Host of AIDS Vaccine 2010 3Health News:Center for AIDS Research at Emory University to Serve as Local Host of AIDS Vaccine 2010 4Health News:Understanding the implications of prenatal testing for Down syndrome 2Health News:SXC Health Solutions teams with Allscripts to deliver critical prescription information to physicians at the point-of-care 2Health News:SXC Health Solutions teams with Allscripts to deliver critical prescription information to physicians at the point-of-care 3Health News:SXC Health Solutions teams with Allscripts to deliver critical prescription information to physicians at the point-of-care 4Health News:SXC Health Solutions teams with Allscripts to deliver critical prescription information to physicians at the point-of-care 5Health News:National Certification for Medical Interpreters - Public Call for Final Written Pilot Exam 2
Measles IgM ELISA....
Toxo IgG ELISA. All Wampole ELISA kits include the following: 12 x 8 well strips with breakaway wells, sample diluent, controls and calibrators, conjugate, TMB substrate, wash buffer, stop solution,...
ELISA kit for CMV CAP M....
Cytomegalovirus IgM ELISA....
Medicine Products: